Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
A selective dopamine D1-receptor agonist, CY 208-243, was administered to 23 de novo patients who had had Parkinson disease (PD) for less than or equal to 3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D2-receptor agonist, bromocriptine. Results showed that CY 208-243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine less than or equal to 15 mg to CY 208-243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D1-receptor stimulation may result in improvement of motor disability in PD.
Emre
M
M
Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel, Switzerland.
Rinne
U K
UK
Rascol
A
A
Lees
A
A
Agid
Y
Y
Lataste
X
X
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010617:Phenanthridines / Q000627:therapeutic use*; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000502:physiology; D017447:Receptors, Dopamine D1
D000978:Antiparkinson Agents; D007211:Indoles; D010617:Phenanthridines; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; C054531:CY 208-243; D001971:Bromocriptine